ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of Retinal Diseases

Baruch D. Kuppermann; Paul Bernstein; Jordi Mones; Diana V. Do; Ron Neumann; Philip J. Rosenfeld

doi:10.1089/jop.2019.0073

ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of Retinal Diseases

Baruch D. Kuppermann, Paul Bernstein, Jordi Mones, Diana V. Do, Ron Neumann, Philip J. Rosenfeld

Ophthalmology

Research output: Contribution to journal › Review article › peer-review

Abstract

Topics change as time flows. This is especially true in retinal therapeutics that merely 25 years ago was mainly a surgical field and in two decades has been transformed into a classic pharmacologic medical field. That said, the classic questions of pharmacology such as pharmacokinetics, pharmacodynamics, dosing and delivery systems currently engage most retina specialists. It was therefore easy for us to focus the 2018 ISOPT Clinical retinal discussions on delivery systems, drug efficacy and classic questions such as: have we reached the unbreakable glass ceiling of efficacy in wet age-related macular degeneration (AMD)? Can we aim our target to achieve an even higher effect? Can it be reached by new chemical/biological entities or would delivery system allow us to reach higher points of efficacy? The discussion also addressed the issue of dry AMD and the glorious parade of failures so far, and how do we measure success and failure via relevant endpoints.

Original language	English (US)
Pages (from-to)	424-432
Number of pages	9
Journal	Journal of Ocular Pharmacology and Therapeutics
Volume	35
Issue number	8
DOIs	https://doi.org/10.1089/jop.2019.0073
State	Published - Oct 2019

Keywords

AMD dry & wet
clinical trials
endpoints
retina
retinal imaging

ASJC Scopus subject areas

Ophthalmology
Pharmacology
Pharmacology (medical)

Access to Document

10.1089/jop.2019.0073

Fingerprint Dive into the research topics of 'ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of Retinal Diseases'. Together they form a unique fingerprint.

Cite this

@article{ac22f4021e504e9cb3371933fd0d54f6,

title = "ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of Retinal Diseases",

abstract = "Topics change as time flows. This is especially true in retinal therapeutics that merely 25 years ago was mainly a surgical field and in two decades has been transformed into a classic pharmacologic medical field. That said, the classic questions of pharmacology such as pharmacokinetics, pharmacodynamics, dosing and delivery systems currently engage most retina specialists. It was therefore easy for us to focus the 2018 ISOPT Clinical retinal discussions on delivery systems, drug efficacy and classic questions such as: have we reached the unbreakable glass ceiling of efficacy in wet age-related macular degeneration (AMD)? Can we aim our target to achieve an even higher effect? Can it be reached by new chemical/biological entities or would delivery system allow us to reach higher points of efficacy? The discussion also addressed the issue of dry AMD and the glorious parade of failures so far, and how do we measure success and failure via relevant endpoints.",

keywords = "AMD dry & wet, clinical trials, endpoints, retina, retinal imaging",

author = "Kuppermann, {Baruch D.} and Paul Bernstein and Jordi Mones and Do, {Diana V.} and Ron Neumann and Rosenfeld, {Philip J.}",

note = "Funding Information: Diana V. Do: Yes, thank you. My talk is, {\textquoteleft}{\textquoteleft}Can We Do Better than VEGF Blockade?{\textquoteright}{\textquoteright} And my disclosures, I{\textquoteright}ve served as a research consultant and also have research grants from Genentech, Regeneron, Bayer and Santen. Publisher Copyright: {\textcopyright} Copyright 2019, Mary Ann Liebert, Inc., publishers 2019. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = oct,

doi = "10.1089/jop.2019.0073",

language = "English (US)",

volume = "35",

pages = "424--432",

journal = "Journal of Ocular Pharmacology and Therapeutics",

issn = "1080-7683",

publisher = "Mary Ann Liebert Inc.",

number = "8",

}

TY - JOUR

T1 - ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of Retinal Diseases

AU - Kuppermann, Baruch D.

AU - Bernstein, Paul

AU - Mones, Jordi

AU - Do, Diana V.

AU - Neumann, Ron

AU - Rosenfeld, Philip J.

N1 - Funding Information: Diana V. Do: Yes, thank you. My talk is, ‘‘Can We Do Better than VEGF Blockade?’’ And my disclosures, I’ve served as a research consultant and also have research grants from Genentech, Regeneron, Bayer and Santen. Publisher Copyright: © Copyright 2019, Mary Ann Liebert, Inc., publishers 2019. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/10

Y1 - 2019/10

N2 - Topics change as time flows. This is especially true in retinal therapeutics that merely 25 years ago was mainly a surgical field and in two decades has been transformed into a classic pharmacologic medical field. That said, the classic questions of pharmacology such as pharmacokinetics, pharmacodynamics, dosing and delivery systems currently engage most retina specialists. It was therefore easy for us to focus the 2018 ISOPT Clinical retinal discussions on delivery systems, drug efficacy and classic questions such as: have we reached the unbreakable glass ceiling of efficacy in wet age-related macular degeneration (AMD)? Can we aim our target to achieve an even higher effect? Can it be reached by new chemical/biological entities or would delivery system allow us to reach higher points of efficacy? The discussion also addressed the issue of dry AMD and the glorious parade of failures so far, and how do we measure success and failure via relevant endpoints.

AB - Topics change as time flows. This is especially true in retinal therapeutics that merely 25 years ago was mainly a surgical field and in two decades has been transformed into a classic pharmacologic medical field. That said, the classic questions of pharmacology such as pharmacokinetics, pharmacodynamics, dosing and delivery systems currently engage most retina specialists. It was therefore easy for us to focus the 2018 ISOPT Clinical retinal discussions on delivery systems, drug efficacy and classic questions such as: have we reached the unbreakable glass ceiling of efficacy in wet age-related macular degeneration (AMD)? Can we aim our target to achieve an even higher effect? Can it be reached by new chemical/biological entities or would delivery system allow us to reach higher points of efficacy? The discussion also addressed the issue of dry AMD and the glorious parade of failures so far, and how do we measure success and failure via relevant endpoints.

KW - AMD dry & wet

KW - clinical trials

KW - endpoints

KW - retina

KW - retinal imaging

UR - http://www.scopus.com/inward/record.url?scp=85073100162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073100162&partnerID=8YFLogxK

U2 - 10.1089/jop.2019.0073

DO - 10.1089/jop.2019.0073

M3 - Review article

C2 - 31596664

AN - SCOPUS:85073100162

VL - 35

SP - 424

EP - 432

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 8

ER -

ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of Retinal Diseases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this